Status:
UNKNOWN
Interleukin-34 Level in Periodontal Disease
Lead Sponsor:
Ain Shams University
Conditions:
Periodontal Disease Stage 2
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
Aim of the study: 1. To investigate changes in the levels of Interleukin 34 (IL-34) in the Gingival crevicular fluid(GCF) of patients with stage II periodontitis patients before and after nonsurgical...
Detailed Description
Periodontal disease is a chronic disease of various inflammatory diseases where the early symptoms are gingival redness, swelling, and bleeding. As the disease progresses, periodontal pockets, clinica...
Eligibility Criteria
Inclusion
- Patients with stage II Periodontitis.
- Both genders aged from 20-50 years
- Minimum 20 natural teeth excluding third molars
- Good compliance with the plaque control instructions following initial therapy.
- Availability for follow-up and maintenance program.
Exclusion
- .•Smokers
- Pregnant and lactating females.
- Systemic diseases that could affect the outcome of the therapy (According to Cornell Medical Index-Health Questionnaire).
- Patients taking antibiotics, anti-inflammatory, and immunosuppressive therapy during the preceding 3 months before the start of the trial and during the study.
- Patients who have undergone any periodontal therapy in the last 6 months
- Vulnerable groups of patients e.g. (handicapped patients).
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05962567
Start Date
January 1 2023
End Date
September 1 2023
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Dentistry-Ain Shams University
Cairo, Egypt